T3 is the Technology Transfer office of the Technion – Israel’s first and leading Institute of Technology. T3’s mission is to cultivate Technion’s human capital and unparalleled wealth of knowledge, linking academy and industry to commercialize and democratize sustainable, high-impact technologies for the future. Our open-to-industry approach is based on the Technion’s longstanding entrepreneurial culture and a commitment to nurture relationships with prestigious industry institutions and businesses. T3 equips researchers with a wealth of resources and guidance to ensure that each discovery is ready to impact, and attract investors looking to access the Technion’s finest intellectual property and leverage our expertise to create promising spin-off companies. T3’s reflection of the innovative strength of Israel's top institute of technology is demonstrated in over 100 affiliated companies established based on the intellectual property generated at the Technion’s ecosystem. Our portfolio includes 7 publicly traded with total valuation over $13.5BD, as well as globally recognized success stories such as Azilect (Teva), Novocure (NASDAQ:NVCR), Corindus (Siemens Healthcare), Mazor (Medtronic), Pluristem (NASDAQ:PSTI), Adicet Bio (NASDAQ:ACET), Rewalk (NASDAQ : RWLK), Inray (Shamir), Invision Biometrics (Intel), Itamar Medical (Zoll Medical). The Technion is home of some of the world’s most prominent life changing technologies. Its multi tier diversified funding and investment channels allow the Technion the ability to continue to generate innovations and products. The funding is geared to serve breadth of funding needs as well as depth. T3 offers acceleration and maturation programs based on industry funded research and applied research funds, as well as investments in existing or new start-up companies from early stages to Round B.